SPI 015
Latest Information Update: 21 Feb 2018
At a glance
- Originator Sucampo Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
- 14 Nov 2005 No development reported - Phase-II for Glaucoma in USA (Ophthalmic)
- 01 Oct 2003 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)